ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
Overall ACAD gets a fundamental rating of 6 out of 10. We evaluated ACAD against 567 industry peers in the Biotechnology industry. ACAD has only an average score on both its financial health and profitability. ACAD has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, ACAD could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
In the past 5 years ACAD reported 4 times negative net income.
In multiple years ACAD reported negative operating cash flow during the last 5 years.
1.2 Ratios
ACAD has a Return On Assets of 19.07%. This is amongst the best in the industry. ACAD outperforms 98.06% of its industry peers.
Looking at the Return On Equity, with a value of 30.90%, ACAD belongs to the top of the industry, outperforming 98.42% of the companies in the same industry.
ACAD's Return On Invested Capital of 9.33% is amongst the best of the industry. ACAD outperforms 95.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.07% | ||
| ROE | 30.9% | ||
| ROIC | 9.33% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 23.64%, ACAD belongs to the top of the industry, outperforming 96.83% of the companies in the same industry.
The Operating Margin of ACAD (8.80%) is better than 94.01% of its industry peers.
Looking at the Gross Margin, with a value of 91.46%, ACAD belongs to the top of the industry, outperforming 91.90% of the companies in the same industry.
ACAD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.8% | ||
| PM (TTM) | 23.64% | ||
| GM | 91.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
The number of shares outstanding for ACAD has been increased compared to 1 year ago.
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACAD has an Altman-Z score of 2.25. This is not the best score and indicates that ACAD is in the grey zone with still only limited risk for bankruptcy at the moment.
ACAD has a better Altman-Z score (2.25) than 73.77% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 2.25 |
ROIC/WACC0.91
WACC10.2%
2.3 Liquidity
ACAD has a Current Ratio of 2.38. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.38, ACAD is not doing good in the industry: 71.48% of the companies in the same industry are doing better.
ACAD has a Quick Ratio of 2.32. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACAD (2.32) is worse than 70.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 2.32 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 226.32% over the past year.
The Revenue has grown by 31.85% in the past year. This is a very strong growth!
ACAD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.08% yearly.
EPS 1Y (TTM)226.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.14%
Revenue 1Y (TTM)31.85%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%12.36%
3.2 Future
The Earnings Per Share is expected to grow by 42.50% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.13% on average over the next years. This is quite good.
EPS Next Y37.87%
EPS Next 2Y44.51%
EPS Next 3Y44.58%
EPS Next 5Y42.5%
Revenue Next Year9.05%
Revenue Next 2Y9.47%
Revenue Next 3Y9.92%
Revenue Next 5Y10.13%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 30.69, ACAD can be considered very expensive at the moment.
ACAD's Price/Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 94.54% of the companies in the same industry.
ACAD is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.79, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 22.26, ACAD is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 93.84% of the companies in the same industry.
ACAD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.69 | ||
| Fwd PE | 22.26 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 97.89% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 95.95% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.63 | ||
| EV/EBITDA | 8.43 |
4.3 Compensation for Growth
ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 44.58% in the coming years.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y44.51%
EPS Next 3Y44.58%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.73
-0.1 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.79%
Inst Owner Change0.92%
Ins Owners0.29%
Ins Owner Change2.42%
Market Cap2.46B
Analysts75.38
Price Target24.71 (67.75%)
Short Float %9.43%
Short Ratio9.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-33.55%
Min EPS beat(2)-109.07%
Max EPS beat(2)41.97%
EPS beat(4)3
Avg EPS beat(4)13.05%
Min EPS beat(4)-109.07%
Max EPS beat(4)109.49%
EPS beat(8)5
Avg EPS beat(8)17.39%
EPS beat(12)8
Avg EPS beat(12)17.44%
EPS beat(16)11
Avg EPS beat(16)18.74%
Revenue beat(2)0
Avg Revenue beat(2)-4.83%
Min Revenue beat(2)-8.33%
Max Revenue beat(2)-1.34%
Revenue beat(4)1
Avg Revenue beat(4)-3.03%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.66%
Revenue beat(8)4
Avg Revenue beat(8)-0.27%
Revenue beat(12)5
Avg Revenue beat(12)-1.32%
Revenue beat(16)6
Avg Revenue beat(16)-2.26%
PT rev (1m)0.43%
PT rev (3m)-1.05%
EPS NQ rev (1m)4.87%
EPS NQ rev (3m)130.35%
EPS NY rev (1m)-10.82%
EPS NY rev (3m)-14.98%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)2.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.69 | ||
| Fwd PE | 22.26 | ||
| P/S | 2.57 | ||
| P/FCF | 15.63 | ||
| P/OCF | 15.58 | ||
| P/B | 3.35 | ||
| P/tB | 4.01 | ||
| EV/EBITDA | 8.43 |
EPS(TTM)0.48
EY3.26%
EPS(NY)0.66
Fwd EY4.49%
FCF(TTM)0.94
FCFY6.4%
OCF(TTM)0.95
OCFY6.42%
SpS5.74
BVpS4.39
TBVpS3.68
PEG (NY)0.81
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.07% | ||
| ROE | 30.9% | ||
| ROCE | 10.63% | ||
| ROIC | 9.33% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 8.8% | ||
| PM (TTM) | 23.64% | ||
| GM | 91.46% | ||
| FCFM | 16.41% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score4
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 3.29% | ||
| Cap/Sales | 0.05% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 157.46% | ||
| Profit Quality | 69.42% | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 2.32 | ||
| Altman-Z | 2.25 |
F-Score4
WACC10.2%
ROIC/WACC0.91
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)226.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.14%
EPS Next Y37.87%
EPS Next 2Y44.51%
EPS Next 3Y44.58%
EPS Next 5Y42.5%
Revenue 1Y (TTM)31.85%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%12.36%
Revenue Next Year9.05%
Revenue Next 2Y9.47%
Revenue Next 3Y9.92%
Revenue Next 5Y10.13%
EBIT growth 1Y214.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.91%
EBIT Next 3Y45.61%
EBIT Next 5Y46.95%
FCF growth 1Y773.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y844.31%
OCF growth 3YN/A
OCF growth 5YN/A